<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01777802</url>
  </required_header>
  <id_info>
    <org_study_id>12-008383</org_study_id>
    <nct_id>NCT01777802</nct_id>
  </id_info>
  <brief_title>Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy</brief_title>
  <acronym>SBRT</acronym>
  <official_title>Observational Study of Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Success of cancer immunotherapy is limited by the ability of solid tumors to evade local and
      systemic antitumoral immune responses. Several mechanisms of tumor immune evasion have been
      identified, including low intratumor expression of antigens and elevated expression of
      inhibitory co-regulatory molecules. An effective immunotherapy is one which would induce
      necrotic cell death and accompanying proinflammatory cytokine induction. Stereotactic Body
      Radiotherapy (SBRT) or Intensity Modulated Radiotherapy (IMRT) or brachytherapy, which is
      capable of delivering high, conformal radiation doses (&gt;8 Gy) of tumor ablative radiation may
      be an effective means of conditioning a tumor bed to a state favorable to the initiation of
      robust antitumoral immune responses.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in immune biomarkers from baseline and after radiation treatments for breast, prostate, and lung cancers.</measure>
    <time_frame>Before and after SBRT, IMRT, or brachytherapy</time_frame>
    <description>Changes in baseline circulating tumor reactive immune markers after radiotherapy.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Prostate Cancer</arm_group_label>
    <description>Patients with prostate cancer will be treated with SBRT, IMRT or brachytherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breast Cancer</arm_group_label>
    <description>Patients with breast cancer will be treated with SBRT, IMRT or brachytherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lung Cancer</arm_group_label>
    <description>Patients with lung cancer will be treated with SBRT, IMRT or brachytherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melanoma Cancer</arm_group_label>
    <description>Patients with melanoma cancer will be treated with SBRT, IMRT or brachytherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <arm_group_label>Prostate Cancer</arm_group_label>
    <arm_group_label>Breast Cancer</arm_group_label>
    <arm_group_label>Lung Cancer</arm_group_label>
    <arm_group_label>Melanoma Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <arm_group_label>Prostate Cancer</arm_group_label>
    <arm_group_label>Breast Cancer</arm_group_label>
    <arm_group_label>Lung Cancer</arm_group_label>
    <arm_group_label>Melanoma Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Brachytherapy</intervention_name>
    <arm_group_label>Prostate Cancer</arm_group_label>
    <arm_group_label>Breast Cancer</arm_group_label>
    <arm_group_label>Lung Cancer</arm_group_label>
    <arm_group_label>Melanoma Cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Oligometastatic prostate, lung, breast and melanoma patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hormone Refractory, Metastatic Prostate Cancer, Lung Cancer, and Melanoma or Breast
             Cancer

        Exclusion Criteria:

        -Life expectancy of less than 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean S Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Sean S Park, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eugene D Kwon, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Haidong Dong, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth R Olivier, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2013</study_first_submitted>
  <study_first_submitted_qc>January 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2013</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Sean S. Park</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

